Louisa E N Rees 1 , Laszlo Pazmany , Danuta Gutowska-Owsiak , Charlotte F Inman , Anne Phillips , Christopher R Stokes , Nikki Johnston , Jamie A Koufman , Gregory Postma , Michael Bailey , Martin A Birchall
Jun 01 2008
Laryngopharyngeal reflux (LPR) affects up to 20% of Western populations. Although individual morbidity is usually moderate, treatment costs are high and there are associations with other diseases, including laryngeal cancer. To date, there have been no studies of the mucosal immune response to this common inflammatory disease.